Abstract
Left ventricular hypertrophy (LVH) is an independent risk factor for cardiovascular (CV) mortality. The PRECISION trial evaluated the CV safety of celecoxib and nonselective NSAIDs. We assessed the contemporary impact of LVH on CV outcomes diagnosed by EKG in this randomized clinical trial. We
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
